News | February 18, 2022
Health Canada authorizes Novavax Covid-19 vaccine
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Canada
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Canada
Dr. Raman has succeeded Victoria Richon
Funding will support continued advancement of Centauri’s antimicrobial resistance research to identify novel therapeutic candidates using its proprietary Alphamer platform
Despite advances over the past 20 years, ovarian cancer treatment requires better standard of care
Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy
Application based on the pivotal Phase 3 TRANSFORM study in which Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years
Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
Dr. Peter Houghton will lead the research collaboration for GCCRI and is widely regarded as a leading expert in pediatric cancer research and in the development of novel approaches to treating childhood cancers
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
Subscribe To Our Newsletter & Stay Updated
